Blog Posts

Photo from Piet Ost/X

May 8, 2024, 02:11

Piet Ost: RADIOSA trial at ESTRO24

Piet Ost, Assistant Professor of Radiation Oncology at Ghent University, shared on X/Twitter:

“RADIOSA trial:

oligorecurrent PCa SBRT vs SBRT + 6 months ADT
ADT improved bRFS and cRFS
more polymetastatic recurrences in the ADT arm.
would love to see eugonad-relapse free survival.
will be interesting to see QoL data and compare with the DART trial.

ESTRO24.”

Source: Piet Ost/X

ADT bRFS cancer cRFS DART trial ESTRO24 OncoDaily Oncology PCa SBRT Piet Ost polymetastatic recurrences RADIOSA trial SBRT

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC

Hesham ElGhazaly: Global Inclusion in Clinical Trials at Vision Europe 2025

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

Youtube

Voices

Sep 5, 2025, 10:18

Isabel Mestres: I Recently Contributed with an Op-Ed to Resolve Global Health’s New Report

Dialogues

Sep 5, 2025, 10:12

MASCC 2025 Presidential Training Fellowship Spotlight: Celia Díez de los Ríos de la Serna

Voices

Sep 5, 2025, 10:11

Staying Physically Active Isn't Just Personal Care: It's Professional Responsibility - American Cancer Society

Voices

Sep 5, 2025, 09:55

Florian Lordick: Chemoresistance of Novel Therapeutic Approaches for Esophageal Adenocarcinoma

Science

Sep 5, 2025, 09:41

Vivek Subbiah: How Aggressive Brain Tumors Exploit Glucose to Suppress Normal Activity

Voices

Sep 5, 2025, 08:57

Honoring a Life of Compassion and Impact - CancerWorld

Voices

Sep 5, 2025, 08:57

C/Can Advances Breast Imaging Training for Global Cities

FDA Approvals

Sep 5, 2025, 08:44

Olomorasib Receives FDA Breakthrough Therapy Designation for KRAS G12C-Mutant NSCLC

Voices

Sep 5, 2025, 08:36

Miriam Mutebi: Scalpel-Wielding Surgeon is Terrified of Needles - Especially When They’re Aimed at Me

Dialogues

Sep 5, 2025, 08:09

ONCOFFEE: Gabriela Inés Villanueva – From Argentina to the US and Back, Shaping Pediatric Oncology

Dialogues

Sep 5, 2025, 08:07

Roche’s CMO Levi Garraway on Personal Journey, Developing Foundation Medicine, and Cancer Research

Dialogues

Sep 5, 2025, 08:05

What Happens When Cancer Meets a Global Pandemic? | Patient stories